Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;233(19-20):3603-13.
doi: 10.1007/s00213-016-4397-4. Epub 2016 Aug 9.

Cannabigerol Is a Novel, Well-Tolerated Appetite Stimulant in Pre-Satiated Rats

Affiliations
Free PMC article

Cannabigerol Is a Novel, Well-Tolerated Appetite Stimulant in Pre-Satiated Rats

Daniel I Brierley et al. Psychopharmacology (Berl). .
Free PMC article

Abstract

Rationale: The appetite-stimulating properties of cannabis are well documented and have been predominantly attributed to the hyperphagic activity of the psychoactive phytocannabinoid, ∆(9)-tetrahydrocannabinol (∆(9)-THC). However, we have previously shown that a cannabis extract devoid of ∆(9)-THC still stimulates appetite, indicating that other phytocannabinoids also elicit hyperphagia. One possible candidate is the non-psychoactive phytocannabinoid cannabigerol (CBG), which has affinity for several molecular targets with known involvement in the regulation of feeding behaviour.

Objectives: The objective of the study was to assess the effects of CBG on food intake and feeding pattern microstructure.

Methods: Male Lister hooded rats were administered CBG (30-120 mg/kg, per ora (p.o.)) or placebo and assessed in open field, static beam and grip strength tests to determine a neuromotor tolerability profile for this cannabinoid. Subsequently, CBG (at 30-240 mg/kg, p.o.) or placebo was administered to a further group of pre-satiated rats, and hourly intake and meal pattern data were recorded over 2 h.

Results: CBG produced no adverse effects on any parameter in the neuromotor tolerability test battery. In the feeding assay, 120-240 mg/kg CBG more than doubled total food intake and increased the number of meals consumed, and at 240 mg/kg reduced latency to feed. However, the sizes or durations of individual meals were not significantly increased.

Conclusions: Here, we demonstrate for the first time that CBG elicits hyperphagia, by reducing latency to feed and increasing meal frequency, without producing negative neuromotor side effects. Investigation of the therapeutic potential of CBG for conditions such as cachexia and other disorders of eating and body weight regulation is thus warranted.

Keywords: Appetite; Appetitive; Cachexia; Cannabigerol; Cannabis; Consummatory; Feeding; Hyperphagia; Phytocannabinoid; Tolerability.

Conflict of interest statement

The work reported was funded in part by grants to BJW and CMW from GW Research and Otsuka Pharmaceuticals. The original study concept was discussed with the sponsor (GW Research), although all subsequent study design, data collection, analysis and interpretation were conducted independently by the authors. The report was approved by the sponsor company prior to submission, and the authors retain full control of all primary data.

Figures

Fig. 1
Fig. 1
Performance parameters in the static beam test component of the neuromotor tolerability test battery (Experiment 1). Administration of CBG at doses up to 120 mg/kg had no deleterious effects on measures of balance (a, b) or fine motor control (c, d). Data presented as mean ± SEM and analysed by one-way repeated measures ANOVA, all groups n = 12
Fig. 2
Fig. 2
Total food intake and locomotor activity levels during the feeding behaviour test (Experiment 2). Administration of CBG at 120 and 240 mg/kg increased food intake (a) and at 240 mg/kg increased locomotor activity (b). Data presented as mean ± SEM and analysed by one-way repeated measures ANOVA and planned comparisons. All groups n = 16. *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 3
Fig. 3
Appetitive phase feeding behaviour parameters in the feeding behaviour test (Experiment 2). Administration of CBG at 120 and 240 mg/kg increased the number of meals consumed (a) and at 240 mg/kg reduced the latency to onset of feeding (b). Data presented as mean ± SEM and analysed by one-way repeated measures ANOVA and planned comparisons. All groups n = 16. *p < 0.05, **p < 0.01

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

References

    1. Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM. Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. Psychopharmacology. 2016;233:243–254. doi: 10.1007/s00213-015-4100-1. - DOI - PubMed
    1. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol. 2010;159:129–141. doi: 10.1111/j.1476-5381.2009.00515.x. - DOI - PMC - PubMed
    1. De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163:1479–1494. doi: 10.1111/j.1476-5381.2010.01166.x. - DOI - PMC - PubMed
    1. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, Woodcock H, Dorward P, Pigliacampo B, Close S, Platt B, Riedel G. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behavi. Psychopharmacology. 2012;219:859–873. doi: 10.1007/s00213-011-2415-0. - DOI - PubMed
    1. Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf. 2012;11:459–471. doi: 10.1517/14740338.2012.675326. - DOI - PubMed
Feedback